Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Philippines FDA/Servcef

Approved

STANDARD

Servcef

Zeiss Pharmaceuticals Pvt. Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: ea39fb7b4a9a2226
Company: Zeiss Pharmaceuticals Pvt. Ltd.
Type: Standard

Approval Details

Approval Id: ea39fb7b4a9a2226
Drug Approval Philippines Name: Servcef
Product Name: Servcef
Registration Number: DRP-7126-09
Brand Name: Servcef
Generic Name: Cefuroxime (as Sodium)
Dosage Form: Powder For Injection (IM/IV)
Dosage Strength: 750 mg
Manufacturer: Zeiss Pharmaceuticals Pvt. Ltd.
Importer: Sanimed Pharmaceuticals Inc.
Distributor: Truserve Pharmaceutical Distributor
Issuance Date: 28 March 2022
Expiry Date: 29 March 2027
Pharmacologic Category: Antibacterial (Cephalosporin)
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

ea39fb7b4a9a2226

Type

Standard

Back to Philippines FDA Approvals

Servcef - Philippines FDA Drug Approval Details